FOLD 250117 9.00C (FOLD250117C9000) Stock Options, News & Quotes

US OptionsDetailed Quotes

FOLD250117C9000

Watchlist

0.82
0.000.00%

15min DelayTrading Dec 13 10:27 ET

0.00High0.00Low

Intraday

5D
Daily

News

Jefferies Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $18
Moomoo NewsDec 17 08:31 ET · Ratings
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Seeking AlphaDec 13 14:42 ET
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
BenzingaDec 13 14:10 ET
Amicus Therapeutics (FOLD) Is a Top-Ranked Momentum Stock: Should You Buy?
Yahoo FinanceDec 13 09:50 ET
Amicus Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley
Dow JonesDec 13 07:08 ET · Ratings
Morgan Stanley Downgrades Amicus Therapeutics(FOLD.US) to Hold Rating, Cuts Target Price to $12
Moomoo NewsDec 12 20:32 ET · Ratings

Comments

Tonyco

Nov 24 18:26

$Amicus Therapeutics (FOLD.US)$
Enter 9.88 Exit 1 10.85 Exit 2 12.1 Exit 3 14.5
Stop loss according to risk

Meltyy

May 16 01:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

Moomoo AI

Feb 7 06:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Jan 3 05:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Shares Climb 28% But Its Business Is Yet to Catch Up

Mini0n

Sep 28, 2023 11:13

$Amicus Therapeutics (FOLD.US)$ Good thing this didn't have any bad news, jesus